#BIO22: Man­ag­ing a biotech in tur­bu­lent times. 'There's a per­fect shit­show out there'

On Tues­day, June 14, End­points News EIC John Car­roll sat down with a group of biotech ex­ecs to dis­cuss the bear mar­ket for in­dus­try stocks and how they were deal­ing with it. Here’s the con­ver­sa­tion, which has been light­ly edit­ed for brevi­ty.

Mar­tin Mee­son, spon­sor open­ing:

Thank you, John. Hel­lo every­one. My name’s Mar­tin Mee­son, I’m the CEO of Fu­ji­film Diosynth. For those of you who don’t know Fu­ji­film Diosynth, we op­er­ate in the de­vel­op­ment of clin­i­cal and com­mer­cial prod­uct scale up, we have fa­cil­i­ties in Eu­rope and the US, and around about 4,000 em­ploy­ees. We run on av­er­age about 150 pro­grams, so when it comes to man­ag­ing in tur­bu­lent times over the last two years, we’ve had quite a lot of ex­pe­ri­ence of that. Not just keep­ing the clin­i­cal pipelines and the com­mer­cial pipelines open, but al­so our re­sponse to the pan­dem­ic and the mol­e­cules that we’ve had with­in there. One of the phras­es that I coined prob­a­bly about a year ago when we were talk­ing at JP Mor­gan, was I talked about man­ag­ing through tur­bu­lent times. Well, it’s be­come the fact that we are not man­ag­ing and lead­ing through these times, we are man­ag­ing in them, which is why that’s re­al­ly the pur­pose of and the top­ic that we’ve got to­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.